These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9132798)

  • 1. [The use of dot blot method for the estimation of IgG antibodies among persons vaccinated against influenza].
    Siennicka J; Brydak L
    Przegl Epidemiol; 1996; 50(4):407-12. PubMed ID: 9132798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05.
    Müller D; Szucs TD
    Infection; 2007 Oct; 35(5):308-19. PubMed ID: 17885730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of antineuraminidase antibodies in protection against influenza].
    Aymard M; Gerentes L; Kessler N
    Bull Acad Natl Med; 1998; 182(8):1723-36; discussion 1736-7. PubMed ID: 10188318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An electroaerosol device for group vaccination against influenza.
    Grinshpun L; Priimägi L; Subi K; Reinet J; Visnapuu L
    Z Erkr Atmungsorgane; 1978 Mar; 150(3):237-8. PubMed ID: 695738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.
    de Jong JC; Beyer WE; Palache AM; Rimmelzwaan GF; Osterhaus AD
    J Med Virol; 2000 May; 61(1):94-9. PubMed ID: 10745239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004.
    Herrera GA; Iwane MK; Cortese M; Brown C; Gershman K; Shupe A; Averhoff F; Chaves SS; Gargiullo P; Bridges CB
    Vaccine; 2007 Jan; 25(1):154-60. PubMed ID: 17064823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(15):393-8. PubMed ID: 18418344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccination in severely multiply handicapped persons/children.
    Otsuka T; Fujinaka H; Kamimura T; Tanaka Y; Hayakawa H; Sato M; Syoubugawa Y; Saito R; Suzuki H; Tomizawa S
    Vaccine; 2006 May; 24(19):4096-101. PubMed ID: 16600445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons.
    Szucs TD; Müller D
    Vaccine; 2005 Oct; 23(43):5055-63. PubMed ID: 16046035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
    Belshe RB; Gruber WC
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1947-51. PubMed ID: 11779396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.
    Skowronski DM; Masaro C; Kwindt TL; Mak A; Petric M; Li Y; Sebastian R; Chong M; Tam T; De Serres G
    Vaccine; 2007 Apr; 25(15):2842-51. PubMed ID: 17081662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma.
    Brydak LB; Machała M; Centkowski P; Warzocha K; Biliński P
    Vaccine; 2006 Nov; 24(44-46):6620-3. PubMed ID: 16870313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients.
    Cavdar C; Sayan M; Sifil A; Artuk C; Yilmaz N; Bahar H; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):71-6. PubMed ID: 12745749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
    Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
    J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza vaccination coverage rates in Germany a population-based cross-sectional analysis of the seasons 2002/2003 and 2003/2004.
    Müller D; Wutzler P; Szucs TD
    Med Klin (Munich); 2005 Jan; 100(1):6-13. PubMed ID: 15654537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination-induced HI antibody response to intraepidemic influenza A(H3N2) virus variants of the 1996-1997 epidemic season.
    Pyhälä R; Ikonen N; Santanen R; Haanpää M; Visakorpi R; Jäppinen P; Valle M
    J Med Virol; 2001 Nov; 65(3):584-9. PubMed ID: 11596097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.